Polyclonal and monoclonal antibodies for the treatment of influenza

被引：20

作者：

Beigel, John H. ^{[1
]}

机构：

[1] NIAID, 5601 Fishers Lane,Room 7E60,MSC 9826, Rockville, MD 20892 USA

来源：

CURRENT OPINION IN INFECTIOUS DISEASES | 2018年 / 31卷 / 06期

基金：

美国国家卫生研究院;

关键词：

convalescent; immune globulin for intravenous use; immunoglobulin; plasma; DOUBLE-BLIND; CONVALESCENT PLASMA; A H5N1; SAFETY; VIRUS; IMMUNOGLOBULIN; PHARMACOKINETICS; ANTIINFLUENZA; TOLERABILITY; MULTICENTER;

D O I：

10.1097/QCO.0000000000000499

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Purpose of review This review summarizes past and ongoing efforts for using polyclonal and monoclonal antibodies for the treatment of influenza, and is focused on products that have entered clinical trials. Recent findings At least three polyclonal and eight monoclonal antibody products have been tested in clinical trials for the treatment of influenza. Considered across the two classes of therapeutics, these products appear to be safe and well tolerated. However, the efficacy results have been mixed and inconclusive. To date, no products have consistently shown superiority to currently available antivirals. No products within these two classes have been licensed, and several products appear to have stopped further clinical development. There are several ongoing studies that are anticipated to be completed or reported in the next 1-2 years which will be critical for understanding the value of polyclonal and monoclonal antibodies in the treatment of influenza.

引用

页码：527 / 534

页数：8

共 45 条

[1]

Ali O, PHASE 2A STUDY EVALU

[2]

[Anonymous], 2018, THERACLONE SCI PRESE

[3] Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab′)2 fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study [J].

Bal, Celine ;

Herbreteau, Cecile H. ;

Buchy, Philippe ;

Rith, Sareth ;

Zaid, Masliza ;

Kristanto, William ;

Han, Velda ;

Reynaud, Charlotte ;

Granjard, Patrick ;

Lepine, Bertrand ;

Durand, Caroline ;

Tambyah, Paul A. .

LANCET INFECTIOUS DISEASES, 2015, 15 (03) :285-292

[4]

Behring E, 1893, HIST DIPHTHERIA

[5] Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study [J].

Beigel, John H. ;

Voell, Jocelyn ;

Kumar, Parag ;

Raviprakash, Kanakatte ;

Wu, Hua ;

Jiao, Jin-An ;

Sullivan, Eddie ;

Luke, Thomas ;

Davey, Richard T., Jr. .

LANCET INFECTIOUS DISEASES, 2018, 18 (04) :410-418

[6] Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study [J].

Beigel, John H. ;

Tebas, Pablo ;

Elie-Turenne, Marie-Carmelle ;

Bajwa, Ednan ;

Bell, Todd E. ;

Cairns, Charles B. ;

Shoham, Shmuel ;

Deville, Jaime G. ;

Feucht, Eric ;

Feinberg, Judith ;

Luke, Thomas ;

Raviprakash, Kanakatte ;

Danko, Janine ;

O'Neil, Dorothy ;

Metcalf, Julia A. ;

King, Karen ;

Burgess, Timothy H. ;

Aga, Evgenia ;

Lane, H. Clifford ;

Hughes, Michael D. ;

Davey, Richard T. .

LANCET RESPIRATORY MEDICINE, 2017, 5 (06) :500-511

[7]

Bonavia A., 2010, VIRUS ADAPT TREAT, V2, P147

[8] Plague history: Yersin's discovery of the causative bacterium in 1894 enabled, in the subsequent century, scientific progress in understanding the disease and the development of treatments and vaccines [J].

Butler, T. .

CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 (03) :202-209

[9] Use of convalescent plasma therapy in SARS patients in Hong Kong [J].

Cheng, Y ;

Wong, R ;

Soo, YOY ;

Wong, WS ;

Lee, CK ;

Ng, MHL ;

Chan, P ;

Wong, KC ;

Leung, CB ;

Cheng, G .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2005, 24 (01) :44-46

[10] Tackling influenza with broadly neutralizing antibodies [J].

Corti, Davide ;

Cameroni, Elisabetta ;

Guarino, Barbara ;

Kallewaard, Nicole L. ;

Zhu, Qing ;

Lanzavecchia, Antonio .

CURRENT OPINION IN VIROLOGY, 2017, 24 :60-69

← 1 2 3 4 5 →